Two field tests of an AIDS vaccine not only failed to protect people from the virus but may have put them at greater risk, U.S. researchers said.
The results of the worldwide trials prompted scientific inquiry as researchers try to assess what happened and whether they should known the outcome, The Washington Post reported Friday.
Both field tests were halted in September and seven other trials of similarly designed AIDS vaccines have been stopped or postponed indefinitely.
"This is on the same level of catastrophe as the (NASA space shuttle) Challenger disaster," said Robert Gallo, co-discoverer of the human immunodeficiency virus, the virus that causes AIDS, and head of the Institute for Human Virology in Baltimore.
The STEP and Phambili studies used the same vaccine and were stopped when it became evident the studies were futile and possibly harmful, the Post reported.
One hypothesis for what went wrong is the vaccine somehow prepared the immune system to be more susceptible to HIV infection, a scenario that wasn't foreseen or suggested by previous studies, the Post said.
The National Institutes of Health in Bethesda, Md, which funded the trials, will meet week to reassess its AIDS vaccine program.
Copyright 2008 by United Press International
Related stories:
Major shift in HIV prevention priorities needed
According to a new policy analysis led by researchers at the Harvard School of Public Health (HSPH) and the University of California, Berkeley, the most common HIV prevention strategies—condom promotion, HIV testing, treatment of other sexually transmitted infections (STIs), vaccine and microbicide research, and abstinence—are having a limited impact on the predominantly heterosexual epidemics found in Africa. Furthermore, some of the assumptions underlying such strategies—such as poverty or war being major causes of AIDS in Africa—are unsupported by rigorous scientific evidence.
NIAID describes research priorities to fight drug-resistant tuberculosis
Tuberculosis (TB) has long been one of the world’s great killers. Now, forms of drug-resistant TB--multidrug (MDR) and extensively drug-resistant (XDR)--are occurring at an ominous and accelerating rate. To help in the fight against drug-resistant TB, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has formulated an MDR and XDR TB research agenda.
Leading HIV researchers to collaborate on vaccine development
Two global research organizations dedicated to designing a vaccine against HIV – the International AIDS Vaccine Initiative (IAVI), and the Center for HIV/AIDS Vaccine Immunology (CHAVI) – have signed an agreement to work together to address major biological questions that have slowed development of a safe, effective and affordable AIDS vaccine.
Newly developed anti-malarial medicine treats toxoplasmosis
A new drug that will soon enter clinical trials for treatment of malaria also appears to be 10 times more effective than the key medicine in the current gold-standard treatment for toxoplasmosis, a disease caused by a related parasite that infects nearly one-third of all humans—more than two billion people worldwide.
'Good bacteria' in women give clues for slowing HIV transmission
Beneficial bacteria found in healthy women help to reduce the amount of vaginal HIV among HIV-infected women and make it more difficult for the virus to spread, boosting the possibility that “good bacteria” might someday be tapped in the fight against HIV.
Monkeys able to fend off AIDS-like symptoms with enhanced HIV vaccine
Researchers at the University of Pennsylvania School of Medicine have discovered that using an immune system gene to enhance a vaccine used to study HIV in macaque monkeys provides the animals with greater protection against simian HIV (SHIV) than an unmodified vaccine. This multi-year study found that the addition of a molecule called Interleukin-15 effectively boosts the effects of a vaccine derived from the DNA of simian HIV.
The 'MIP-MAP' game: Indian bug is the ancestor of Crohn's disease pathogen
An Indian team of researchers led by Seyed E. Hasnain of the Institute of Life Sciences (ILS), University of Hyderabad, India has found that a seemingly unknown mycobacterial organism Mycobacterium indicus pranii (MIP) could be the earliest ancestor of the 'generalist' branch of mycobacterial pathogens.
Analysis of Chinese AIDS epidemic shows surprising patterns
The mountainous Chinese province of Yunnan is tucked into the country’s southwest corner, a scenic region that borders Burma, Laos and Vietnam. The province shares its rugged topography with the surrounding countries, but it shares a less favorable trait as well: a growing AIDS epidemic, driven by a thriving underground commercial sex trade and by heroin smuggled in from the opium-growing regions of its three neighbors, an area known as the “golden triangle.”